Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Eric B Rimm a Department of Nutrition, Harvard School
of Public Health, Boston, MA 02115, USA, b Department of Biostatistics, Harvard School of Public Health, c San Diego
School of Medicine and Family and Preventive Medicine, University of
California at San Diego, CA 92093, USA
Correspondence to: E B Rimm
eric.rimm{at}channing.harvard.edu
| |
Abstract |
|---|
|
|
|---|
Objective:
To summarise quantitatively the association between moderate alcohol intake and biological markers of risk of
coronary heart disease and to predict how these changes would lower the risk.
Design:
Meta-analysis of all experimental studies that
assessed the effects of moderate alcohol intake on concentrations of
high density lipoprotein cholesterol, apolipoprotein A I, fibrinogen, triglycerides, and other biological markers previously found to be
associated with risk of coronary heart disease.
Participants:
Men and women free of previous chronic
disease and who were not dependent on alcohol. Studies were included in which biomarkers were assessed before and after participants consumed up to 100 g of alcohol a day.
Interventions:
Alcohol as ethanol, beer, wine, or spirits.
Main outcome measures:
Changes in concentrations of
high density lipoprotein cholesterol, apolipoprotein A I, Lp(a)
lipoprotein, triglycerides, tissue type plasminogen activator activity,
tissue type plasminogen activator antigen, insulin, and glucose
after consuming an experimental dose of alcohol for 1 to 9 weeks; a shorter period was accepted for studies of change in concentrations of
fibrinogen, factor VII, von Willebrand factor, tissue type plasminogen
activator activity, and tissue type plasminogen activator antigen.
Results:
61 data records were abstracted from 42 eligible studies with information on change in biological markers of
risk of coronary heart disease. An experimental dose of 30 g of ethanol a day increased concentrations of high density lipoprotein cholesterol by 3.99 mg/dl (95% confidence interval 3.25 to 4.73), apolipoprotein A
I by 8.82 mg/dl (7.79 to 9.86), and triglyceride by 5.69 mg/dl (2.49 to
8.89). Several haemostatic factors related to a thrombolytic profile
were modestly affected by alcohol. On the basis of published associations between these biomarkers and risk of coronary heart disease 30 g of alcohol a day would cause an estimated reduction of
24.7% in risk of coronary heart disease.
Conclusions:
Alcohol intake is causally related to
lower risk of coronary heart disease through changes in lipids and
haemostatic factors.
|
Key messages
|
| |
Introduction |
|---|
|
|
|---|
The inverse association between moderate alcohol intake and coronary heart disease is documented in over 40 prospective studies in diverse populations.1-5 Men and women who consume one to three drinks a day have a 10% to 40% lower risk of coronary heart disease than those who abstain. In most large studies risk of coronary heart disease decreases in a downward linear fashion with alcohol intake up to three drinks a day.6-9 This reduction is generally attributed to the beneficial effects of alcohol on lipids and haemostatic factors. 5 10-13
Over 75 experimental studies have examined the effects of alcohol
intake on lipids, haemostatic factors, vitamins, glucose, insulin, and
lipid peroxidation.10 w1-w55 However, only a
few epidemiological studies have simultaneously examined the relation
between alcohol intake, biochemical variables, and subsequent risk of
coronary heart disease.w56-w61 From these studies it is
estimated that half of the beneficial effect of moderate alcohol intake
is due to increased high density lipoprotein cholesterol
concentrations. This calculation may, however, be an underestimate
because it does not take into account measurement error in the
assessment of average alcohol intake or biological variability in high
density lipoprotein cholesterol concentrations. In several of these
studies potential confounding by other lifestyle factors
for example,
diet, obesity, and physical activity
was also not considered.
Furthermore, other biochemical variables, such as fibrinogen,
triglycerides, von Willebrand factor, and insulin, were not examined in
these simultaneous models.
We quantitatively summarised the effects of alcohol on a variety of
biomarkers from experimental studies using standard meta-analysis methods, and we projected the impact of those changes on risk of
coronary heart disease using data from published studies relating biomarker concentrations to coronary heart disease.
| |
Methods |
|---|
|
|
|---|
We searched Medline for all experimental studies of alcohol
(ethanol) in humans published in English between 1965 and 1998. We
supplemented our search by examining citations in review
articles,
1 3 14 15
the proceedings of meetings and
symposia, and the Journal of the Alcohol Beverage Medical
Research Foundation and Alcohol Research
journals that
track alcohol related research. We restricted our search to studies in
individuals without diagnosed coronary heart disease, diabetes, or
alcohol dependence. We included only those studies that assessed
biomarkers consistently modified by alcohol and related to risk of
coronary heart disease. For lipid factors we included only studies with
an intervention period of at least seven days; shorter intervals seem
to have little or no effect. We included all studies of coagulation and
thrombolytic factors because effects have been documented within hours
after consumption of alcohol. Although we describe studies of lipid
peroxidation and platelet aggregation we did not include these in our
quantitative analyses because these assays were not comparable across
studies owing to major differences in methodology. Furthermore, most
were assessed with in vitro assays, which have not consistently been linked to risk of coronary heart disease.
In the final analysis we included only studies that provided the number, age range, and sex of the participants, average dose of alcohol, duration of the study, beverage type (beer, wine, spirits, or ethanol), and the change in concentration of a biological marker compared with its pretreatment measurement or a comparable group of placebo or untreated participants. Data were abstracted by two of the authors, and differences were resolved through consultation.
We excluded studies where
100 g of ethanol were consumed a day. For
studies with multiple doses or multiple subpopulations we abstracted a
data record from each study subpopulation. If ethanol was provided on
the basis of the participant's weight we calculated the amount of
ethanol for the average weight of the study participants. In several
studies alcohol was given within strata of obesity or physical
activity. These factors were considered as potential modifiers of the
underlying relation between ethanol and biological variables of
coronary heart disease. In our analysis each subpopulation was
considered as a separate data record.
Statistical methods
For each biological measure we fitted a zero intercept weighted
linear regression model predicting the change in the
biological marker for alcohol intake as a continuous variable. We
fitted intercept models and models with higher order terms, but the
results were not appreciably different from our main analyses and are
not presented. Each study was weighted by the inverse of the variance
of the change measure. If no variance measure was provided we computed
the average weight from the remaining studies. For biological markers
with fewer than 10 data records we weighted the regressions by the size
of the study. Using other weighting schemes did not substantially
change the main results.
| |
Results |
|---|
|
|
|---|
After exclusions we reviewed 42 experimental studies of alcohol, providing 67 separate data records. For the main analysis we excluded six data records from studies in which participants who usually consumed alcohol were restricted from any intake for several weeks, because the baseline measure of alcohol is less precise than in studies in which standard amounts of alcohol were given.
High density lipoprotein cholesterol
Results on change in high density lipoprotein cholesterol
concentrations were available from 36 data records from 25 studies (see
table A on website). After consumption of an average 40.9 g of alcohol
a day for 4.1 weeks, high density lipoprotein cholesterol
concentrations increased by an average of 5.1 mg/dl. In an unweighted
regression model high density lipoprotein cholesterol concentrations
increased by 0.122 mg/dl per gram of alcohol a day (fig 1). After
weighting each study as described high density lipoprotein cholesterol
concentrations increased by 0.133 mg/dl per gram of alcohol consumed a
day. The average individual consuming 30 g of alcohol a day would
expect an increase in high density lipoprotein cholesterol
concentration of 3.99 mg/dl (95% confidence interval 3.25 to 4.73)
compared with an individual who abstains
an 8.3% increase from
pretreatment values (fig
2).
|
|
Apolipoprotein A I
An average of 37.6 g of alcohol a day was consumed for 3.9 weeks
resulting in an increase in apolipoprotein A I concentrations of 11.83 mg/dl. After weighting each of the 24 data records we found a 0.294 mg/dl increase in apolipoprotein A I concentrations per gram of alcohol
consumed a day (P<0.001). The average individual consuming 30 g of
alcohol a day showed an 8.82 mg/dl (7.79 to 9.86) increase in
apolipoprotein A I concentrations (6.5% increase over baseline; fig
2).
Triglycerides
From 35 data records we found that triglyceride concentrations
increased by 0.19 mg/dl per gram of alcohol consumed a day (P=0.001)
and 5.69 mg/dl (2.49 to 8.89) per 30 g consumed a day (5.9% increase
over baseline; fig 2).
Other factors
Alcohol intake has been associated with a favourable thrombolytic
profile in many cross sectional studies
12 13 22-25
and
in several experimental studies (see table B on website). Many studies
have used in vitro or ex vivo measures of platelet aggregation, but
assay methods vary greatly and few such markers have been linked with
risk of coronary heart disease. Only a few studies have assessed
concentrations of fibrinogen, plasminogen, tissue type plasminogen
activator, plasminogen activator inhibitor-1, factor VII, and von
Willebrand factor (see table B on website)
factors that have been
associated with risk of coronary heart disease.26-28 Weighted regression analyses for each of these haemostatic factors was
suggestive of a more thrombolytic profile, but none was significantly affected by moderate alcohol intake (fig 2). From the weighted regression equations an increment of 30 g of alcohol a day was associated with a 7.5 mg/dl (
17.7 to 32.7) decrease in fibrinogen concentration, a 1.25 ng/ml (
0.31 to 2.81) increase in tissue type
plasminogen activator antigen concentration, and a 1.47% (
1.18 to
4.42) increase in plasminogen concentration. Lp(a) lipoprotein
a lipoprotein particle that may affect the fibrinolytic cascade
was only
assessed in four studies (five data records) and was modestly, and
non-significantly, decreased by 0.70 mg/dl (
3.38 to 1.99) for each
30 g increment of alcohol a day. We did not include activity of tissue
type plasminogen activator owing to substantial differences in assay
methods and heterogeneity of results. Furthermore, it is not clear that
acute changes in tissue type plasminogen activator caused by alcohol
intake should be used to determine subsequent risk of coronary heart
disease because concentrations may also be influenced by extent of
existing coronary disease.27 Sufficient data were not
available to calculate a weighted average for von Willebrand factor or
factor VII, but alcohol tended to lower the concentrations of
both.w37 w50
Quantitative prediction of reduction in coronary heart disease
risk among moderate drinkers
Using the effect sizes estimated for a 30 g increase in alcohol
intake a day and results from studies of biological markers and risk of
coronary heart disease we computed the expected change in risk
associated with consuming 30 g of alcohol a day compared with
abstaining. No single epidemiological study has simultaneously
calculated the risk of coronary heart disease associated with all
biological markers. Therefore, we used several similar
studies,
26 29-31
which provided multivariate relative
risk estimates for differences in concentrations of high density
lipoprotein cholesterol, apolipoprotein A I, triglycerides, and
fibrinogen (table).
|
| |
Discussion |
|---|
|
|
|---|
Summary of main findings
In this quantitative review we found strong and consistent
evidence linking moderate alcohol intake with higher concentrations of
high density lipoprotein cholesterol and apolipoprotein A I and lower
concentrations of fibrinogen. We also found a weak association between
moderate alcohol intake and increased triglyceride concentration. On
the basis of published associations between these biomarkers and risk
of coronary heart disease we calculated an overall predicted 24.7%
reduction in risk of coronary heart disease associated with an intake
of 30 g of alcohol a day owing to changes in these markers. These data
support a causal interpretation of the association between moderate
alcohol intake and lower risk of coronary heart disease and suggest
that the benefit is mediated in part through several known biological
markers of coronary heart disease. The data suggest, however, that
other mechanisms are probably involved, but these could not be included
in our analysis owing to lack of available experimental data.
Limitations
Our review has several limitations. Study methods and assay
procedures varied. Even among studies that used similar methods changes
in biological markers may be modified by differences in genetic
predisposition and metabolic ability, diet, smoking patterns, or other
lifestyle factors across populations. Unmeasured biological variability
in response to moderate alcohol intake would attenuate our overall
results. Furthermore, our results are based on experimental studies of
short duration; data are not available to test whether similar effects
would be found with longer studies. None the less, the 24.7% reduction
in risk of coronary heart disease that we predict on the basis of an
intake of 30 g of alcohol a day is comparable to relative risks
reported from several large scale prospective studies of alcohol and
coronary heart disease.
4 6 9
Alcohol and other factors
Too few experimental studies included measures of insulin
sensitivity for us to be able to summarise them. However, several large
cross sectional studies have reported strong positive associations
between alcohol and increased insulin sensitivity.
33 34
Biological mechanisms
As reviewed in detail elsewhere
10 38
alcohol may
directly increase the hepatic production and secretion of apolipoproteins and lipoprotein particles, increase triglyceride lipase concentrations, and decrease removal of circulating high density
lipoprotein cholesterol. The increase in production of extrahepatic
lipoprotein lipases is in response to increased triglyceride concentrations. Lipolysis of triglyceride rich particles increases the
flow of cholesterol to high density lipoprotein particles from
circulating very low density lipoprotein remnants and raises overall
high density lipoprotein concentration. Although speculative, alcohol
may also interfere with the activity of cholesteryl ester transfer
protein
39 40
and reduce the transfer of cholesteryl esters in high density lipoprotein particles to more atherogenic particles. Some investigators have suggested that alcohol may preferentially increase high density lipoprotein-3 particles, which
contain apolipoprotein A I and apolipoprotein A II.
41 42
In the two experimental studies that we summarised, which specifically measured the apolipoprotein content of high density lipoprotein particles, both found an increase in high density lipoprotein particles
with apolipoprotein A I and apolipoprotein A II,w30
w31 but Clevidence et al found a similar increase in high
density lipoprotein particles only containing apolipoprotein A
I.W31 There were insufficient data from
experimental studies of high density lipoprotein subcomponents to
clarify this issue; none the less the importance of high density
lipoprotein subfractions in risk prediction may be minimal if total
high density lipoprotein concentration is considered.w31
| |
Conclusions |
|---|
|
|
|---|
A complete review of the risks and benefits of alcohol intake is
beyond the scope of this meta-analysis. Although alcohol intake is
associated with an increased risk of breast and aerodigestive cancers,
and injury,
7 52
studies on alcohol and mortality suggest
that men and women who consume up to 30 g of alcohol a day have the
lowest overall risk.
7-9 11
Should non-drinkers be
advised to begin drinking? Criqui has argued53 that most non-drinkers abstain for a reason (for example, religion, previous health conditions, family history of alcoholism) and therefore should
not be advised to start drinking. In agreement with this suggestion
current recommendations in the United States and the United Kingdom do
not encourage alcohol intake but do state that moderate intake can be
part of a healthy lifestyle.
54 55
Results from our
quantitative review suggest that moderate intake is causally related to
lower risk of coronary heart disease through alcohol induced changes in
lipids and haemostatic factors.
| |
Acknowledgments |
|---|
Contributors: EBR wrote the paper. EBR and KF conducted the search and abstracted the data for the analysis. EBR and PW performed the statistical analysis. MC and MJS reviewed and edited the paper and provided input into the design and analysis for the study. EBR and MJS will act as guarantors for the paper.
| |
Footnotes |
|---|
Funding: The Europe Alcohol Task Force of the International Life Sciences Institute.
Competing interests: EBR has received both honorariums for speaking at academic conferences and travel expenses from alcohol related organisations.
website extra: Additional references and details of the studies appear on the BMJ's website www.bmj.com
| |
References |
|---|
|
|
|---|
| 1. | Moore RD, Pearson TA. Moderate alcohol consumption and coronary artery disease: a review. Medicine 1986; 65: 242-267[Medline]. |
| 2. | Marmot M, Brunner E. Alcohol and cardiovascular disease: the status of the U-shaped curve. BMJ 1991; 303: 565-568. |
| 3. |
Maclure M.
Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction.
Epidemiol Rev
1993;
15:
328-351 |
| 4. |
Klatsky AL.
Epidemiology of coronary heart disease influence of alcohol.
Alcohol Clin Exp Res
1994;
18:
88-96[Medline].
|
| 5. | Renaud S, Criqui MH, Farchi G, Veenstra J. Alcohol drinking and coronary heart disease. In: Verschuren PM, ed. Health issues related to alcohol consumption. Washington, DC: ILSI Press, 1993:18-124. |
| 6. | Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, et al. A prospective study of alcohol consumption and the risk of coronary disease in men. Lancet 1991; 338: 464-468[Medline]. |
| 7. |
Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath Jr CW, et al.
Alcohol consumption and mortality among middle-aged and elderly U.S. adults.
N Engl J Med
1997;
337:
1705-1714 |
| 8. |
Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, et al.
Alcohol consumption and mortality among women.
N Engl J Med
1995;
332:
1245-1250 |
| 9. |
Doll R, Peto R, Hall E, Wheatley K, Gray R.
Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors.
BMJ
1994;
309:
911-918 |
| 10. | Moore RD, Smith CR, Kwiterovich PO, Pearson TA. Effect of low-dose alcohol use versus abstention on apolipoproteins A-1 and B. Am J Med 1988; 84: 884-890[Medline]. |
| 11. |
Doll R.
One for the heart.
BMJ
1997;
315:
1664-1668 |
| 12. | Reeder Jr VC, Aikens ML, Li XN, Booyse FM. Alcohol and fibrinolytic system. In: Zakhari S, Wassef M, eds. Alcohol and the cardiovascular system, research monograph No 31. Bethesda, MD: National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 1996. |
| 13. | McKenzie CR, Eisenberg PR. Alcohol, coagulation, and arterial thrombosis. In: Zakhari S, Wassef M, eds. Alcohol and the cardiovascular system, research monograph No 3. Bethesda, MD: National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 1996. |
| 14. | Klatsky AL, Armstrong MA, Friedman GD. Alcohol and mortality. Ann Intern Med 1992; 117: 646-654. |
| 15. | Verschuren PME. Health issues related to alcohol consumption. Washington, DC: ILSI Press, 1993:329. |
| 16. | Mosteller F, Chalmers TC. Some progress and problems in meta-analysis of clinical trials. Stat Sci 1992; 7: 227-236. |
| 17. | Smith SJ, Caudill SP, Steinberg KK, Thacker SB. On combining dose-response data from epidemiological studies by meta-analysis. Stat Med 1995; 14: 531-544[Medline]. |
| 18. |
Rosner B, Spiegelman D, Willett WC.
Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error.
Am J Epidemiol
1992;
136:
1400-1413 |
| 19. | Willett WC. Nutritional epidemiology. New York: Oxford University Press, 1990. |
| 20. | Marckmann P, Sandstrom B, Jespersen J. The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis 1992; 96: 235-244[Medline]. |
| 21. |
Rosenson RS, Tangney CC, Hafner JM.
Intraindividual variability of fibrinogen levels and cardiovascular risk profile.
Arterioscler Thromb
1994;
14:
1928-1932 |
| 22. | Meade TW, Chakrabarti R, Haines AP, North WR, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ 1979; 1: 153-156. |
| 23. |
Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH.
Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator.
JAMA
1994;
272:
929-933 |
| 24. | Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plama fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205[Medline]. |
| 25. | Renaud SC, Ruf JC. Effects of alcohol on platelet functions. Clin Chimica Acta 1996; 246: 77-89[Medline]. |
| 26. | Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 1986; 2: 533-537[Medline]. |
| 27. | Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168[Medline]. |
| 28. |
Ernst E, Resch KL.
Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.
Ann Intern Med
1993;
118:
956-963 |
| 29. | Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381[Abstract]. |
| 30. |
Stampfer MJ, Krauss RM, Ma J, Blance PJ, Holl LG, Sacks FM, et al.
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.
JAMA
1996;
276:
882-888 |
| 31. |
Friedman LA, Kimball AW.
Coronary heart disease mortality and alcohol consumption in Framingham.
Am J Epidemiol
1986;
124:
481-489 |
| 32. |
Jacobs Jr DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA, for the Lipid Research Clinics.
High density lipoprotein cholesterol as a predictor of cardiovascular disease mortalilty in men and women: the follow-up study of the lipid research clinics prevalence study.
Am J Epidemiol
1990;
131:
32-47 |
| 33. |
Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, et al.
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study).
BMJ
1996;
313:
1040-1044 |
| 34. |
Vitelli LL, Folsom AR, Shahar E, Winkhart SP, Shirnakawa T, Stevens J, et al.
Association of dietary composition with fasting serum insulin level the ARIC study.
Nutr Metab Cardiovasc Dis
1996;
6:
194-202.
|
| 35. |
Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, et al.
A prospective study of nutritional factors and hypertension among US men.
Circulation
1992;
86:
1475-1484 |
| 36. |
Puddey IB, Beilin LJ, Vandongen R, Rouse IL, Rogers P.
Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men. A randomized controlled trial.
Hypertension
1985;
7:
707-713 |
| 37. | Camargo Jr CA, Rimm EB. Epidemiologic research on moderate alcohol consumption and blood pressure. In: Alcohol and cardiovascular system, research monograph 31. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 1996:25-62. (Publication No 96-4133.) |
| 38. | Savolainen MJ, Kesaniemi YA. Effects of alcohol on lipoproteins in relation to coronary heart disease. Curr Opin Lipidol 1995; 6: 243-250[Medline]. |
| 39. | Hannuksela M, Marcel YL, Kesaniemi YA, Savolainen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 1992; 33: 737-744[Abstract]. |
| 40. | Hannuksela ML, Rantala M, Kesaniemi YA, Savolainen MJ. Alcohol-induced redistribution of cholesteryl ester transfer protein (CETP) between lipoproteins. Circulation 1992; 86(suppl): 2756. (Abstract.) |
| 41. | Branchi A, Rovellini A, Tomella C, Sciariada L, Torri A, Molgora M, et al. Association of alcohol consumption with HDL subpopulations defined by apolipoprotein A-I and apolipoprotein A-II content. Eur J Clin Nutr 1997; 1997: 362-365. |
| 42. |
Puchois P, Ghalim N, Zylberberg G, Fievet P, Demarquilly C, Fruchart JC.
Effect of alcohol intake on human apolipoprotein A-I containing lipoprotein subfractions.
Arch Intern Med
1990;
150:
1638-1641 |
| 43. | Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2: 986-988[Medline]. |
| 44. | Rand ML, Gross PL, Jakowec DM, Packham MA, Mustard JF. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin. Thromb Haemostasis 1989; 61: 254-258[Medline]. |
| 45. | Stubbs CD, Rubin R. Effect of ethanol on platelet phospholipase A2. Lipids 1992; 27: 255-260[Medline]. |
| 46. |
Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JWG.
Ischemic heart disease and platelet aggregation: the Caerphilly collaborative heart disease study.
Circulation
1991;
83:
38-44 |
| 47. |
Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al.
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.
J Am Coll Cardiol
1998;
31:
352-358 |
| 48. | Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988; 319: 267-273[Abstract]. |
| 49. |
Rosenberg L, Slone D, Shapiro S, Kaufman DW, Miettinen OS, Stolley PD.
Alcoholic beverages and myocardial infarction in young women.
Am J Public Health
1981;
71:
82-85 |
| 50. | Klatsky AL, Armstrong MA, Friedman GD. Red wine, white wine, liquor, beer, and risk of coronary artery disease hospitalization. Am J Cardiol 1997; 80: 416-420[Medline]. |
| 51. |
Rehm JT, Bondy SJ, Sempos CT, Vuong CV.
Alcohol consumption and coronary heart disease morbidity and mortality.
Am J Epidemiol
1997;
146:
495-501 |
| 52. |
Smith-Warner SA, Spiegelman D, Yaun S-S, Adami HO, van den Brandt PA, Folsom AR, et al.
Alcohol and breast cancer in women: a pooled analysis of cohort studies.
JAMA
1998;
279:
535-540 |
| 53. | Criqui MH. Alcohol and coronary heart disease risk: implications for public policy. J Stud Alcohol 1997; 58: 453-454[Medline]. |
| 54. | Food and Nutrition Board. Recommended dietary allowances, 10th revised ed. Washington, DC: National Academy of Sciences, 1989. |
| 55. | Department of Health. Interdepartmental working group. In: Sensible drinking. Wetherby: DoH, 1995. |
(Accepted 7 September 1999)
Read all Rapid Responses